CEO share purchase

Dr Martens

16/06/2026 07:00

RNS Number : 3333I
  
Dr. Martens PLC
  
16 June 2026
  
 


16 June 2026
Dr. Martens plc (the 'Company')
CEO Share Purchase
Notification of Transactions by Director / Person Discharging Managerial Responsibility
The Company announces that it has been notified that Ije Nwokorie, Chief Executive Officer and PDMR, purchased 112,500 ordinary shares of 1 pence each in the Company ('Ordinary Shares') on 12 June 2026 at a price of £0.761 per Ordinary Share.
The relevant notification, set out below, is provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.
 




1


Details of the person discharging managerial responsibilities/person closely associated




a)


Name


Ije Nwokorie




2


Reason for the notification




a)


Position/status


PDMR (Chief Executive Officer)




b)


Initial notification/Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Dr. Martens plc




b)


LEI


213800QPT8YM6NQZPH28




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument
Identification code


Ordinary shares of GBP 0.01


ISIN: GB00BL6NGV24




b)


Nature of the transaction


Purchase of Ordinary Shares




c)


Price(s) and volume(s)






 


Price(s)


Volume(s)








£0.761


112,500










d)


Aggregated information
 




-


Aggregated volume




-


Price






 


 


 
 
112,500

£0.761




e)


Date of the transaction


12 June 2026




f)


Place of the transaction


London Stock Exchange (XLON)




 
For further information please contact:
Bethany Barnes, Director of Investor Relations and Corporate Communications
+4478 2518 7465
 
Paul Rolling, Head of Secretariat
+4475 8424 3562
 
ENDS

 About Dr. Martens
Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot - named after the date it was produced - rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, "Docs" or "DM's" were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.
Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people. The company continues to honour the brand's heritage through its 'Made in England' footwear, manufactured at its original Northamptonshire factory, while meeting global demand from multiple high-quality production sites across Asia. All our products are made with an unwavering commitment to craft, combined with innovative techniques.
A brand built to put a bounce in the step of those who stand out from the crowd, Dr. Martens is available through Direct-to-Consumer (Retail and Ecommerce) and Wholesale channels. The brand's collections range from its Original silhouettes - The Icons such as the 1460 boot, 1461 shoe, 2976 Chelsea boot, and Adrian loafer - to modern franchises like the Zebzag, Buzz, and Lowell. The lineup also includes an extensive range of sandals, a dedicated Kids collection, and a curated selection of bags, small leather goods, and accessories.
Every Dr. Martens product reflects craftsmanship, heritage, timeless style, comfort, and versatility. Having transcended generations, the brand stays as relevant today as it was at its inception. Its signature yellow welt stitching, grooved sole edges, and scripted "With Bouncing Soles" heel loops remain iconic symbols recognised around the world.
Dr. Martens plc (DOCS.L) is listed on the main market of the London Stock Exchange and is a constituent of the FTSE 250 index.
For more information, visit www.drmartens.com or www.drmartensplc.com 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHSFFFSIEMSEDM